Search results for "Amide"

showing 10 items of 3119 documents

Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature.

2015

Importance BRAF inhibitors have been licensed for the therapy of BRAF-mutated melanoma. Recently, inflammatory skin lesions clinically resembling erythema nodosum have been reported as therapy side-effects that may lead to treatment discontinuation. Objective To identify and characterize cases with BRAF inhibitor-associated erythema nodosum-like inflammatory skin lesions and development of an algorithm for their management. Design and Setting Retrospective chart review of melanoma patients treated with BRAF inhibitors in 14 departments of Dermatology in Germany and Austria and PubMed search for cases in the literature. Results Sixteen patients were identified who developed erythema nodosum-…

AdultMaleProto-Oncogene Proteins B-rafmedicine.medical_specialtyIndolesErythemaBiopsyMedizinDermatology030207 dermatology & venereal diseases03 medical and health sciencesYoung Adult0302 clinical medicineErythema NodosumOximesmedicineHumansskin and connective tissue diseasesVemurafenibneoplasmsAgedRetrospective StudiesSkinTrametinibErythema nodosumSulfonamidesintegumentary systembusiness.industryMelanomaImidazolesDabrafenibMiddle Agedmedicine.diseaseDermatology3. Good healthInfectious DiseasesVemurafenib030220 oncology & carcinogenesisFemalemedicine.symptombusinessPanniculitisVasculitismedicine.drugJournal of the European Academy of Dermatology and Venereology : JEADV
researchProduct

Human dopamine receptor D2/D3 availability predicts amygdala reactivity to unpleasant stimuli

2009

r r Abstract: Dopamine (DA) modulates the response of the amygdala. However, the relation between dopa- minergic neurotransmission in striatal and extrastriatal brain regions and amygdala reactivity to affective stimuli has not yet been established. To address this issue, we measured DA D2/D3 receptor (DRD2/3) availability in twenty-eight healthy men (nicotine-dependent smokers and never-smokers) using positron emission tomography with ( 18 F)fallypride. In the same group of participants, amygdala response to unpleasant visual stimuli was determined using blood oxygen level-dependent (BOLD) functional mag- netic resonance imaging. The effects of DRD2/3 availability in emotion-related brain …

AdultMalePyrrolidinesEmotionsNeurotransmissionAmygdalaDopamine receptor D3DopamineDopamine receptor D2medicineHumansRadiology Nuclear Medicine and imagingPrefrontal cortexResearch ArticlesBrain MappingRadiological and Ultrasound TechnologyReceptors Dopamine D2SmokingReceptors Dopamine D3Tobacco Use DisorderAmygdalaMagnetic Resonance ImagingOxygenmedicine.anatomical_structureNeurologyFallyprideCerebrovascular CirculationPositron-Emission TomographyBenzamidesVisual PerceptionAnxietyNeurology (clinical)Anatomymedicine.symptomPsychologyNeurosciencePhotic Stimulationmedicine.drug
researchProduct

The applicability of SRTM in [18F]fallypride PET investigations: Impact of scan durations

2011

The high-affinity radioligand [18F]fallypride (FP) is frequently used for quantification of striatal/extrastriatal D2/3 receptors and the receptor occupancies of antipsychotics (APs). Its 110 minutes half-life allows long scan durations. However, the optimum scan duration is a matter of debate. This investigation focuses on scan-duration-related effects on simplified reference tissue model (SRTM) results and the time point of transient equilibrium in a large sample of dynamic FP positron emission tomography (PET) scans. Fifty drug-free and 50 AP-treated subjects underwent FP-PET scans (180 minutes scan duration). The binding potential ( BPND) of the putamen, thalamus, and temporal cortex w…

AdultMalePyrrolidinesTime FactorsMaterials scienceAdolescentShuttle Radar Topography MissionRadioligand AssayYoung AdultRadioligandmedicineHumansTemporal cortexTransient equilibriummedicine.diagnostic_testReceptors Dopamine D2business.industryMental DisordersPutamenReceptors Dopamine D3Binding potentialMiddle AgedCorpus StriatumNeurologyFallypridePositron emission tomographyPositron-Emission TomographyBenzamidesFemaleOriginal ArticleNeurology (clinical)Cardiology and Cardiovascular MedicineNuclear medicinebusinessAntipsychotic AgentsJournal of Cerebral Blood Flow & Metabolism
researchProduct

Dopamine D2/D3 receptor availability and venturesomeness.

2011

The construct of impulsivity is considered as a major trait of personality. There is growing evidence that the mesolimbic dopamine system plays an important role in the modulation of impulsivity and venturesomeness, the two key components within the impulsivity-construct. The aim of the present study was to explore an association between trait impulsivity measured with self-assessment and the dopaminergic neurotransmission as measured by positron emission tomography (PET) in a cohort of healthy male subjects. In vivo D2/D3 receptor availability was determined with [(18)F]fallypride PET in 18 non-smoking healthy subjects. The character trait impulsivity was measured using the Impulsiveness-V…

AdultMaleSelf-AssessmentPyrrolidinesStatistics as TopicNeuroscience (miscellaneous)Neuropsychological TestsImpulsivityStatistical parametric mappingPersonality AssessmentBrain mappingDevelopmental psychologyCohort StudiesYoung AdultRisk-TakingDopamine receptor D3Dopamine receptor D2Surveys and QuestionnairesmedicineHumansRadiology Nuclear Medicine and imagingTemporal cortexBrain MappingReceptors Dopamine D2BrainPsychiatry and Mental healthFallypridePositron-Emission TomographyBenzamidesImpulsive Behaviormedicine.symptomPersonality Assessment InventoryPsychologyNeurosciencePsychiatry research
researchProduct

Ezetimibe/Simvastatin 10/20 mg versus Rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency

2010

Abstract Objective This post-hoc analysis compared the lipid-altering efficacy of Ezetimibe/Simvastatin 10/20 mg (EZ/Simva) versus Rosuvastatin 10 mg (Rosuva) in patients stratified by statin potency/dose prior to randomization. Methods Patients with elevated low-density lipoprotein cholesterol (LDL-C) despite prior statin treatment (n = 618) were randomized 1:1 to EZ/Simva 10/20 mg or Rosuva 10 mg for 6 weeks. Percent change from baseline in lipids and attainment of lipid targets were assessed within each subgroup (low potency n = 369, high potency n = 249). Consistency of the treatment effect across subgroups was evaluated by testing for treatment-by-subgroup interaction. No multiplicity …

AdultMaleSimvastatinmedicine.medical_specialtySettore MED/09 - Medicina InternaStatinRandomizationAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismHypercholesterolemiaClinical BiochemistryUrologyPharmacologyYoung AdultEndocrinologyEzetimibemedicineHumansPotencyRosuvastatinRosuvastatin Calciumlcsh:RC620-627AgedBiochemistry medicalAged 80 and overSulfonamidesSimvastatin; Ezetimibe;hypercholesterolemic;ChemistryhypercholesterolemicResearchAnticholesteremic AgentsBiochemistry (medical)nutritional and metabolic diseasesMiddle AgedEzetimibeFluorobenzeneslcsh:Nutritional diseases. Deficiency diseasesRosuvastatin CalciumPyrimidinesTreatment OutcomeSimvastatinAzetidinesFemalelipids (amino acids peptides and proteins)Ezetimibe/simvastatinHydroxymethylglutaryl-CoA Reductase Inhibitorsmedicine.drugLipids in Health and Disease
researchProduct

Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately c…

2009

SUMMARY Aims: To evaluate the efficacy of switching from a previous statin monotherapy to ezetimibe ⁄simvastatin (EZE ⁄SIMVA) 10 ⁄20 mg vs. rosuvastatin (ROSUVA) 10 mg. Methods: In this randomised, double-blind study, 618 patients with documented hypercholesterolaemia [low-density lipoprotein cholesterol (LDL-C) ‡ 2.59 and £ 4.92 mmol ⁄l] and with high cardiovascular risk who were taking a stable daily dose of one of several statin medications for ‡ 6 weeks prior to the study randomisation visit entered a 6-week open-label stabilisation ⁄screening period during which they continued to receive their prestudy statin dose. Following stratification by study site and statin dose ⁄potency, patien…

AdultMaleSimvastatinmedicine.medical_specialtyimvastatinStatinmedicine.drug_classHypercholesterolemiaCoronary Artery DiseaseGastroenterologyhypercholesterolaemicchemistry.chemical_compoundDouble-Blind MethodEzetimibeRisk FactorsInternal medicinemedicineHumansRosuvastatinRosuvastatin CalciumAgedAged 80 and overSulfonamidesbiologybusiness.industryCholesterolCholesterol LDLGeneral MedicineMiddle AgedFluorobenzenesRosuvastatin CalciumPyrimidinesTreatment OutcomeEndocrinologychemistrySimvastatinHMG-CoA reductasebiology.proteinAzetidinesDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Ezetimibe/simvastatinHydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessezetimibemedicine.drugInternational Journal of Clinical Practice
researchProduct

Loss of the preconditioning effect of rosuvastatin during sustained therapy: a human in vivo study

2011

Studies have demonstrated that the acute administration of 3-hydroxy-3 methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors has protective effects in the setting of ischemia-reperfusion (IR). Previously, we demonstrated that a single dose of rosuvastatin prevented IR-induced endothelial dysfunction in humans through a cyclooxygenase-2-dependent mechanism. Whether the chronic administration of HMG-CoA reductase inhibitors provides similar protection remains controversial and is unknown in humans. Eighteen male volunteers were randomized to receive a single dose of rosuvastatin (20 mg) or placebo. Twenty-four hours later, endothelium-dependent, radial artery flow-mediated dilation (FMD) w…

AdultMaleTime FactorsAdolescentEndotheliumPhysiologyCoenzyme AHyperemiaPharmacologyReductaseDrug Administration ScheduleYoung Adultchemistry.chemical_compoundDouble-Blind MethodIschemiaIn vivoPhysiology (medical)medicineHumansRosuvastatinRosuvastatin CalciumOntarioAnalysis of VarianceSulfonamidesCyclooxygenase 2 Inhibitorsbiologybusiness.industryFluorobenzenesVasodilationRosuvastatin CalciumPyrimidinesmedicine.anatomical_structurechemistryCelecoxibRegional Blood FlowReperfusion InjuryRadial ArteryHMG-CoA reductasebiology.proteinCelecoxibPyrazolesHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessBlood Flow Velocitymedicine.drugAmerican Journal of Physiology-Heart and Circulatory Physiology
researchProduct

Agomelatine and Hepatotoxicity: Implications of Cumulated Data Derived from Spontaneous Reports of Adverse Drug Reactions

2013

Considering the antidepressant agomelatine (AGM) there is a discrepancy between the widespread knowledge of the potential of AGM to cause hepatotoxic adverse drug reactions (ADR) and the availability of corresponding published data. This impedes an adequate assessment of the hepatotoxicity profile of AGM. We conducted a query of the database of a German Medical Regulatory Body (BfArM) and analyzed spontaneous reports of hepatotoxic ADR. We identified n=58 cases of AGM-related hepatotoxic ADR. Most frequent ADR was asymptomatic increase of liver enzymes (79%); n=6 patients (10%) with AGM-related toxic hepatitis were reported. Characteristics of patients: female sex (69%), age > 50 years (mea…

AdultMaleToxic hepatitismedicine.medical_specialtyDatabases FactualPharmacologyAsymptomaticLiver diseaseRisk FactorsGermanyInternal medicineAcetamidesPharmacovigilancemedicineHumansAgomelatinePharmacology (medical)ContraindicationAgedAged 80 and overPolypharmacybusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseAntidepressive AgentsDiscontinuationPsychiatry and Mental healthFemaleChemical and Drug Induced Liver Injurymedicine.symptombusinessmedicine.drugPharmacopsychiatry
researchProduct

Management and long-term follow-up of early stage H. pylori-associated gastric MALT-lymphoma in clinical practice: An Italian, multicentre study

2009

Abstract Background/Aim Data on management and long-term follow-up of Helicobacter pylori -associated MALT-lymphoma in clinical practice are scanty. We evaluate the long-term efficacy of H. pylori eradication on low-grade MALT-lymphoma, and the efficacy of further therapies in refractory patients. Methods This study enrolled patients with stages I–II 1 MALT-lymphoma and H. pylori infection. H. pylori eradication was attempted in all patients. Patients with lymphoma persistence or progression following H. pylori treatments received further lymphoma treatments. Both 5-year and disease-free survivals were calculated. Results Sixty patients (stage I/II 1 : 50/10) were followed up for a median t…

AdultMaleVincristinemedicine.medical_specialtyCyclophosphamideSettore MED/12 - GASTROENTEROLOGIAGastric maltomamanagementKaplan-Meier EstimateGastroenterologyDisease-Free SurvivalHelicobacter InfectionsYoung AdultStomach Neoplasmsimmune system diseasesPrednisonehemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansYoung adultCyclophosphamideAgedRetrospective StudiesAged 80 and overHelicobacter pyloriHepatologybiologybusiness.industryGastroenterologyProton Pump InhibitorsMALT lymphomaRetrospective cohort studyLymphoma B-Cell Marginal ZoneMiddle AgedHelicobacter pyloribiology.organism_classificationmedicine.diseaseAnti-Bacterial AgentsLymphomaSurgeryItalyDoxorubicinVincristinePrednisoneFemalebusinessFollow-Up Studiesmedicine.drug
researchProduct

Multiclonal Synovial T Cell Response toYersinia enterocoliticain Reactive Arthritis: TheYersinia61-kDa Heat-Shock Protein Is Not the Major Target Ant…

1993

The T cell response to bacterial antigens plays a major role in the pathogenesis of reactive arthritis (ReA) following enteric infections with Yersinia enterocolitica. To study the antigen specificity of the T cells at the site of inflammation, the response of cloned T cells from the synovial fluid of 2 patients with ReA to partially purified antigens of Yersinia enterocolitica was determined. The clones showed different patterns of response to various fractions, indicating a multiclonal response to Yersinia antigens, and these specificities differed in the 2 patients. Some T cells were specific for Y. enterocolitica; some cross-reacted with other enterobacteria. Proteins of 14 and 19 kDa c…

AdultMaleYersinia InfectionsT-LymphocytesT cellCross ReactionsBiologyYersiniaArthritis ReactiveMicrobiologyEpitopesAntigenHeat shock proteinProhibitinsSynovial FluidmedicineHumansImmunology and AllergyYersinia enterocoliticaChromatography High Pressure LiquidHeat-Shock ProteinsYersinia enterocoliticaAntigens BacterialImmunity CellularYersiniosismedicine.diseasebiology.organism_classificationInfectious Diseasesmedicine.anatomical_structureChromatography GelbacteriaElectrophoresis Polyacrylamide GelBacterial antigenSynovial membraneJournal of Infectious Diseases
researchProduct